Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer

Lancet Oncol. 2021 Aug;22(8):1056-1058. doi: 10.1016/S1470-2045(21)00405-8.
No abstract available

Publication types

  • Comment

MeSH terms

  • Biomarkers
  • Carcinoma, Non-Small-Cell Lung* / diagnostic imaging
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Humans
  • Lung Neoplasms* / drug therapy
  • Neoadjuvant Therapy / adverse effects

Substances

  • Biomarkers